JEGI LEONIS Has Advised Forge, a Portfolio Company of Apollo, on Their Definitive Agreement to Acquire Becker's Healthcare, a Portfolio Company of Pamlico Capital

Apollo-backed Forge has agreed to acquire Becker's Healthcare from Pamlico Capital, expanding its healthcare and life-sciences media and events footprint. Becker's reaches more than 1.5 million healthcare leaders digitally and hosts over 15,000 annual live-event attendees. Combined with Forge's Fierce Healthcare and Life Sciences assets, the platform will span more than 35 live events and provide year-round media, digital products and executive communities across biotech, pharma, providers and payers.

Analysis

This is strategically more relevant to private-market valuation than to APO’s near-term earnings. The transaction reinforces Apollo’s playbook of consolidating fragmented B2B information assets around proprietary executive audiences, where cross-selling sponsorships, data products and events can lift revenue per customer and reduce customer-acquisition costs. The key economic question is whether Forge can monetize overlapping healthcare advertiser budgets without cannibalizing its existing properties; absent purchase price, financing and pro forma EBITDA disclosure, there is no basis to underwrite incremental fee-related earnings for APO.

The more investable second-order read is competitive: scaled healthcare-information platforms can command a greater share of pharma, medtech and hospital vendor marketing spend, pressuring smaller specialist publishers and event operators that lack first-party audience data. RELX and WLY are structurally better insulated because their healthcare products are embedded in workflow, research and clinical decision-making rather than primarily marketing-led engagement; nevertheless, a successful Forge integration could raise private-market comparables for adjacent B2B media assets over the next 6-18 months.

Consensus should avoid treating this as an APO catalyst. Apollo’s public valuation will remain driven by fundraising, deployment, realizations and fee-related earnings, while this asset combination is too small and too opaque to move those variables directly. The useful near-term signal is whether subsequent Forge acquisitions are financed with incremental debt: an aggressive roll-up funded at high private-credit spreads would increase refinancing risk and could turn a multiple-expansion narrative into a leverage concern within 12-24 months.

Key Decisions for Investors

• No directional APO trade on this announcement alone; maintain existing exposure only if core alternatives-platform catalysts remain intact. Reassess if Apollo discloses a material equity commitment, transaction-financing terms, or an impact on fee-related earnings guidance.
• Set an alert on Forge’s next acquisition or debt issuance over the next 3-6 months. Repeated acquisitions with rising leverage or materially wider financing spreads would be a negative read-through for Apollo’s portfolio-mark risk; disclosed EBITDA synergies and stable leverage would support the roll-up thesis.
• Monitor RELX and WLY against smaller healthcare-media/private-event comparables over 6-18 months rather than initiating a pair trade now. A sustained premium in private transaction multiples could modestly support RELX/WLY sum-of-the-parts valuations, but their direct revenue exposure to this competitive set is insufficient for a standalone catalyst trade.